202 related articles for article (PubMed ID: 22310927)
21. Long-term safety and efficacy of AAV gene therapy in the canine model of glycogen storage disease type Ia.
Lee YM; Conlon TJ; Specht A; Coleman KE; Brown LM; Estrella AM; Dambska M; Dahlberg KR; Weinstein DA
J Inherit Metab Dis; 2018 Nov; 41(6):977-984. PubMed ID: 29802554
[TBL] [Abstract][Full Text] [Related]
22. Recombinant AAV-directed gene therapy for type I glycogen storage diseases.
Chou JY; Mansfield BC
Expert Opin Biol Ther; 2011 Aug; 11(8):1011-24. PubMed ID: 21504389
[TBL] [Abstract][Full Text] [Related]
23. Gene therapy for type I glycogen storage diseases.
Chou JY; Mansfield BC
Curr Gene Ther; 2007 Apr; 7(2):79-88. PubMed ID: 17430128
[TBL] [Abstract][Full Text] [Related]
24. Molecular biology and gene therapy for glycogen storage disease type Ib.
Chou JY; Cho JH; Kim GY; Mansfield BC
J Inherit Metab Dis; 2018 Nov; 41(6):1007-1014. PubMed ID: 29663270
[TBL] [Abstract][Full Text] [Related]
25. Challenges of Gene Therapy for the Treatment of Glycogen Storage Diseases Type I and Type III.
Jauze L; Monteillet L; Mithieux G; Rajas F; Ronzitti G
Hum Gene Ther; 2019 Oct; 30(10):1263-1273. PubMed ID: 31319709
[TBL] [Abstract][Full Text] [Related]
26. Pathogenesis of growth failure and partial reversal with gene therapy in murine and canine Glycogen Storage Disease type Ia.
Brooks ED; Little D; Arumugam R; Sun B; Curtis S; Demaster A; Maranzano M; Jackson MW; Kishnani P; Freemark MS; Koeberl DD
Mol Genet Metab; 2013 Jun; 109(2):161-70. PubMed ID: 23623482
[TBL] [Abstract][Full Text] [Related]
27. Gene therapy prevents hepatic tumor initiation in murine glycogen storage disease type Ia at the tumor-developing stage.
Cho JH; Lee YM; Starost MF; Mansfield BC; Chou JY
J Inherit Metab Dis; 2019 May; 42(3):459-469. PubMed ID: 30637773
[TBL] [Abstract][Full Text] [Related]
28. Mice expressing reduced levels of hepatic glucose-6-phosphatase-α activity do not develop age-related insulin resistance or obesity.
Kim GY; Lee YM; Cho JH; Pan CJ; Jun HS; Springer DA; Mansfield BC; Chou JY
Hum Mol Genet; 2015 Sep; 24(18):5115-25. PubMed ID: 26089201
[TBL] [Abstract][Full Text] [Related]
29. Rescue administration of a helper-dependent adenovirus vector with long-term efficacy in dogs with glycogen storage disease type Ia.
Crane B; Luo X; Demaster A; Williams KD; Kozink DM; Zhang P; Brown TT; Pinto CR; Oka K; Sun F; Jackson MW; Chan L; Koeberl DD
Gene Ther; 2012 Apr; 19(4):443-52. PubMed ID: 21654821
[TBL] [Abstract][Full Text] [Related]
30. Adenovirus-mediated gene therapy in a mouse model of glycogen storage disease type 1a.
Chou JY; Zingone A; Pan CJ
Eur J Pediatr; 2002 Oct; 161 Suppl 1():S56-61. PubMed ID: 12373573
[TBL] [Abstract][Full Text] [Related]
31. Adeno-associated virus-mediated correction of a canine model of glycogen storage disease type Ia.
Weinstein DA; Correia CE; Conlon T; Specht A; Verstegen J; Onclin-Verstegen K; Campbell-Thompson M; Dhaliwal G; Mirian L; Cossette H; Falk DJ; Germain S; Clement N; Porvasnik S; Fiske L; Struck M; Ramirez HE; Jordan J; Andrutis K; Chou JY; Byrne BJ; Mah CS
Hum Gene Ther; 2010 Jul; 21(7):903-10. PubMed ID: 20163245
[TBL] [Abstract][Full Text] [Related]
32. Preclinical Development of New Therapy for Glycogen Storage Diseases.
Sun B; Brooks ED; Koeberl DD
Curr Gene Ther; 2015; 15(4):338-47. PubMed ID: 26122079
[TBL] [Abstract][Full Text] [Related]
33. Correction of glycogen storage disease type 1a in a mouse model by gene therapy.
Zingone A; Hiraiwa H; Pan CJ; Lin B; Chen H; Ward JM; Chou JY
J Biol Chem; 2000 Jan; 275(2):828-32. PubMed ID: 10625614
[TBL] [Abstract][Full Text] [Related]
34. Pathogenesis of Hepatic Tumors following Gene Therapy in Murine and Canine Models of Glycogen Storage Disease.
Kang HR; Gjorgjieva M; Smith SN; Brooks ED; Chen Z; Burgess SM; Chandler RJ; Waskowicz LR; Grady KM; Li S; Mithieux G; Venditti CP; Rajas F; Koeberl DD
Mol Ther Methods Clin Dev; 2019 Dec; 15():383-391. PubMed ID: 31890731
[TBL] [Abstract][Full Text] [Related]
35. Gene therapy for glycogen storage diseases.
Kishnani PS; Sun B; Koeberl DD
Hum Mol Genet; 2019 Oct; 28(R1):R31-R41. PubMed ID: 31227835
[TBL] [Abstract][Full Text] [Related]
36. Glycogen storage disease type I and G6Pase-β deficiency: etiology and therapy.
Chou JY; Jun HS; Mansfield BC
Nat Rev Endocrinol; 2010 Dec; 6(12):676-88. PubMed ID: 20975743
[TBL] [Abstract][Full Text] [Related]
37. Normoglycemia alone is insufficient to prevent long-term complications of hepatocellular adenoma in glycogen storage disease type Ib mice.
Yiu WH; Pan CJ; Mead PA; Starost MF; Mansfield BC; Chou JY
J Hepatol; 2009 Nov; 51(5):909-17. PubMed ID: 19376605
[TBL] [Abstract][Full Text] [Related]
38. Systemic Correction of Murine Glycogen Storage Disease Type IV by an AAV-Mediated Gene Therapy.
Yi H; Zhang Q; Brooks ED; Yang C; Thurberg BL; Kishnani PS; Sun B
Hum Gene Ther; 2017 Mar; 28(3):286-294. PubMed ID: 27832700
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II.
Sun B; Zhang H; Franco LM; Young SP; Schneider A; Bird A; Amalfitano A; Chen YT; Koeberl DD
Mol Ther; 2005 Jan; 11(1):57-65. PubMed ID: 15585406
[TBL] [Abstract][Full Text] [Related]
40. Gene therapy for glycogen storage diseases.
Koeberl DD; Koch RL; Lim JA; Brooks ED; Arnson BD; Sun B; Kishnani PS
J Inherit Metab Dis; 2024 Jan; 47(1):93-118. PubMed ID: 37421310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
